TrialMuscle & nerve2022

Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.

Jeffrey M Statland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.